The current financial score of TherapeuticsMD Inc is 8.54. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 869.00K, representing a year-over-year decrease of 8.72%, while its net profit experienced a year-over-year decrease of 71.87%.
The current valuation score of TherapeuticsMD Inc is 9.18. Its current P/E ratio is 140.10, which is 5.05% below the recent high of 147.17 and 131.93% above the recent low of -44.73.
No earnings forecast score is currently available for TherapeuticsMD Inc. The Pharmaceuticals industry's average is 7.83.
The current price momentum score of TherapeuticsMD Inc is 3.75. Currently, the stock price is trading between the resistance level at 2.33 and the support level at 2.02, making it suitable for range-bound swing trading.
The current institutional shareholding score of TherapeuticsMD Inc is 3.00. The latest institutional shareholding proportion is 32.99%, representing a quarter-over-quarter increase of 14.39%. The largest institutional shareholder is James Simons, holding a total of 146.60K shares, representing 0.00% of shares outstanding, with 2247.37% increase in holdings.
The current risk assessment score of TherapeuticsMD Inc is 4.13. The company's beta value is 0.60. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.